Affiliation:
1. Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy
Abstract
Background:
Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently
used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma
and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated.
Method:
We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury
(AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced
nephropathy.
Results:
Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI,
when used before the development of the kidney damage. Positive results were also obtained in the
management of intensive care unit patients with AKI, although the clinical studies investigated were
few and conducted on small samples.
Conclusion:
Conflicting results were achieved in contrast-induced nephropathy.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献